Hemas Holdings Ltd. · CSELK:HHL.N0000
Hemas — Q4 FY23/24 Earnings Presentation
31 slides from Hemas's earnings presentation, 2024
Slide 1: Hemas Holdings PLC Investor Presentation Q4 FY23/24
Hemas Holdings PLC Investor Presentation- Q4 FY23/24
Slide 2: Who we are
Who we are Established in 1948, with a purpose of empowering families to live a better tomorrow, Hemas Holdings is one of Sri Lanka’s leading conglomerates listed in the Colombo Stock exchange with focused interest in Consumer and Healthcare. Key Milestones “Established Hemas Drugs Pvt 1948 Ltd” “IP
Slide 3: Implications of key macro economic parameters on Hemas
Implications of key macro economic parameters on Hemas Interest Rates Stable Exchange Rates Global Commodity prices “A gradual decline in AWPLR was “ Mixed impact of reduced prices of witnessed during the year easing the “Positive impact from reduced RM key commodities which contributed pressure on
Slide 4: Key strengths
BOM Group CEO Nomination & Governance Committee Human Related Party Resources & Transactions Board Remuneration Review Committee Committee Investment Group Audit Committee Committee Diversified and competent Presence in key defensive segments Leadership Team Healthcare and Consumer Sound Corporate G
Slide 5: Corporate Governance
Corporate Governance BOM Group CEO BOM (Board of Management) Nomination & Consists of the senior leadership team of 11 members - Heads of our 6 businesses and 5 leaders from Corporate Governance Office. BOM is responsible for formulation and implementation of Group strategic plan and ensures that th
Slide 6: Strategic Building Blocks
Strategic Building Blocks Building more from New within the core New business and Efficiencies the core and Adjacencies Internationalisation Accelerate current business Capturing new revenue Explore attractive Efficiency and productivity to efforts to drive higher value streams to further strengthen
Slide 7: New Product Launches during the Quarter
New Product Launches during the Quarter Home and Personal Care Pharmaceutical Manufacturing ‘Clogard’ Pro Clean Paracetamol Tablets B.P. 500mg Additions to the ‘Velvet Naturals’ Range Losartan Potassium Tablets B.P. 50mg ‘Dandex’ Detox ‘Kumarika’ and Cleanse Cooling Oil Shampoo ‘Fems’ Ultra Thin
Slide 8: Financial Snapshot
Financial Snapshot EBIT by Segment (LKR million) 2,767 280 3,004 3,133 12M contribution to the Group 211 1,529 211 57% 1% 1,318 351 42% 3,103 251 2,171 37% 9% Revenue 255 1,843 650 886 63% EBIT 741 831 930 726 952 (193) (308) (466) (260) Consumer Healthcare Mobility FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 F
Slide 9: Sector Performance Summary – Q4 FY 2023-24
Sector Performance Summary – Q4 FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 1,525 113 -2,394 -13 31,440 32,209 519 141 -204 -327 3,133 3,004 Q4 FY 23 Healthcare Mobility Other Consumer Q4 FY 24 Q4 FY 23 Others Mobility Healthcare Consumer Q4 FY 24
Slide 10: Sector Performance Summary – 12M FY 2023-24
Sector Performance Summary – 12M FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 1,699 -104 -363 3,155 -274 11,921 4,453 64 3 121,614 113,940 10,963 12M FY 23 Consumer Healthcare Mobility Other 12M FY 24 12M FY 23 Consumer Other Mobility Healthcare 12M FY 24
Slide 11: Continuing Operation EPS – Q4 FY 2023-24
Continuing Operation EPS – Q4 FY 2023-24 EPS Walk (LKR Per Share) 0.32 -0.77 0.22 1.10 2.64 0.63 0.12 -0.63 2.64 0.75 1.77 1.77 Q4 FY 23 Net Finance NCI Operating Income Tax Q4 FY 24 Q4 FY 23 Other Healthcare Mobility Consumer Q4 FY 24 Cost Profit
Slide 12: Continuing Operation EPS – 12M FY 2023-24
Continuing Operation EPS – 12M FY 2023-24 EPS Walk (LKR Per Share) -0.70 0.93 10.24 1.25 1.60 3.06 -0.10 -0.30 10.24 0.42 7.16 7.16 12M FY 23 Operating Net Finance NCI Income Tax 12M FY 24 12M FY 23 Consumer Healthcare Others Mobility 12M FY 24 Profit Cost
Slide 13: Capital Employed – FY 2023-24
Capital Employed – FY 2023-24 Sector Efficiency Capital Employed, ROCE, and EBIT by Sector 80% Mobility LKR 1,102.7 Mn Consumer 63.9% LKR 7,569.4 Mn 60% 40% 39.9% Healthcare Group ROCE :22.1% LKR 4,384.9 Mn ROCE (%) 20% 14.7% 0% 0 5 10 15 20 25 30 35 -20% -17.6% Capital Employed (LKR Bn) Other LKR (
Slide 14: Consumer Brands
Consumer Brands Home and personal care - Sri-Lanka Consumer Brands - International Learning Segment
Slide 15: Consumer Brands
Consumer Brands Contribution to Group Sector Performance – 12M FY 2023-24 Key Highlights Revenue % 42% • Consumer dynamics witnessed signs of Revenue (LKR Mn) -15.8% recovery during the quarter with both 12M FY24 modern and general trade channels 40% (YoY) 12M FY23 witnessing growth. 15,135 15,433 1
Slide 16: Home and Personal Care – Sri Lanka
Home and Personal Care – Sri Lanka 8 Key categories with market Purpose-driven brands touching the lives of the Sri Lankan consumer leading positions Extensions to the ‘Velvet’ and ‘Clogard’ Portfolio Inclusive Strong roots Parenting Stronger Make a Celebrating Enabling Both parents together Positiv
Slide 17: Home and Personal Care – International
Home and Personal Care – International Locally led and localised in Bangladesh Reach in Bangladesh 2 Geographies Bangladesh & West Bengal • All products are exclusively designed for Bangladesh. Rural penetration by • Extensive product portfolio with multiple value 19.3% Hemas Key categories 3 • Valu
Slide 18: Home and Personal Care – Sri Lanka and International
Home and Personal Care – Sri Lanka and International Sri Lanka International Revenue (LKR Mn) 0.9% Revenue Revenue (YoY) • The Home and Personal Care Business posted 8,446 8,606 8,803 8,371 a volume growth with improved market share 8,000 7,767 • With the collective success of the ‘Actisef’ brand, t
Slide 19: Learning Segment
Learning Segment Revenue 6 Key categories • Improved its market leading position with the increase in market share in all three segments: premium, mass and value-for-money. Revenue (LKR Mn) • Atlas World’, the integrated platform for the Atlas Axillia community including ‘Atlas My High Efficiency an
Slide 20: Healthcare Sector
Healthcare Sector Pharmaceutical Import, Marketing and Distribution Pharmaceutical Manufacturing Hospitals
Slide 21: Healthcare
Healthcare Contribution to Group Sector Performance – 12M FY 2023-24 Revenue % 57% 9.1% Key Highlights Revenue (LKR Mn) (YoY) 12M FY24 12M FY23 57% 17,639 17,912 18,237 18,000 16,712 15,326 • Despite some strides made in 16,000 addressing drug shortages, the 14,000 12,000 persistent shortage of heal
Slide 22: Pharmaceutical Import, Marketing, Distribution and Manufacturing
Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing Revenue 8.8% • The business extended its portfolio by introducing over 40 new products Revenue (LKR Mn) (YoY) during the quarter into the market mainly in critical NCD spaces. • The branded generics portfolio continued t
Slide 23: Hospitals
Hospitals Revenue 190+ Beds • Collective impact of improved total admissions and theatre utilisation coupled with increase in revenue from the Revenue (LKR Mn) laboratory chain resulted in a double-digit revenue growth in the Hospitals Business 12.3 % • New initiatives including Ambulatory Surgical
Slide 24: Mobility Sector
Mobility Sector Maritime Aviation
Slide 25: Mobility
Mobility Contribution to Group Sector Performance – 12M FY 2023-24 1% Revenue % Revenue (LKR Mn) Key Highlights 32.% 12M FY24 1% (YoY) 12M FY23 460 458 • Despite the challenges witnessed in the 500 418 376 global maritime space, the Port of 400 345 Colombo (POC) witnessed a growth in 300 transshipme
Slide 26: Environmental Agenda 2030
Environmental Agenda 2030 ENCOURAGING RESPONSIBLE PROTECTING SRI LANKAN ENDEMISM PLASTIC CONSUMPTION Protection of 10 critically endangered 500,000+ KG endemic species. The Group is To Date Plastic Collection committed to protect 52 by 2030 REDUCTION OF PLASTIC USAGE IN PACKAGING SAFEGUARDING OUR EC
Slide 27: Social Impact: 399,900+ Families Empowered
Social Impact: 399,900+ Families Empowered TACKLING PERIOD POVERTY PROVIDING WIGS TO CANCER PATIENTS CREATING A SAFER WORLD CREATING EQUAL LEARNING OPPURTUNITY 85,500 2,016 38,290 97,205 Women and Girls Women Families Children, Teachers and Parents CREATING QUALITY LEARNING TACKLING DIABETES EMPOWER
Slide 28: Sustainability Performance – Q4 2023-24 vs Q4 2022-23
Sustainability Performance – Q4 2023- 24 vs Q4 2022 - 23 Values of Fines for Non-Compliance Carbon Footprint (per Rs. Mn Revenue) 7.1% 0.13MT with Laws and Regulations in the NONE Social Economic Area Water Consumption Total Work-Related Injury Rate (per Rs. Mn Revenue) 1.5 m3 (per 100 employee) 0.4
Slide 29: The Group's Strategy
The Group’s Strategy Refreshing the portfolio High growth spaces • Pursuing scalable opportunities across current • Consumer Brands seeks to extend its presence and new verticals in Sri Lanka, Bangladesh, rest in the Personal Care and Beauty categories. of South Asia and East Africa. • Hospitals wil
Slide 30: Corporate and BU Priorities
Focus on Personal care, Beauty and wellness Focus Areas with a drive for premiumiation and exploring underpenetrated Markets Corporate Priorities Strengthening value prepositions to grow market share Accelerating the M&A opportunities Accelerate exports and international expansion Consumer through O
Slide 31: Disclaimer / Thank You
Disclaimer The material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this